Journal ArticleDOI
Cancer immunotherapy – revisited
TLDR
The recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.Abstract:
Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of evaluation, and financial support. Although durable clinical remissions have been observed with various immunotherapeutic strategies, the percentage of patients who benefited from these interventions has remained too small to justify the general use of such strategies. However, the recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.read more
Citations
More filters
Journal ArticleDOI
The secret ally: immunostimulation by anticancer drugs
TL;DR: The molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications, are discussed.
Journal ArticleDOI
Turning the corner on therapeutic cancer vaccines
TL;DR: Key steps are highlighted that are bringing the promise of therapeutic cancer vaccines within reach, including learning which vaccine approaches elicit the potent, balanced, and durable CD4 plus CD8 T cell expansion necessary for clinical efficacy.
Journal ArticleDOI
Classification of current anticancer immunotherapies
Lorenzo Galluzzi,Erika Vacchelli,José Manuel Bravo-San Pedro,Aitziber Buqué,Laura Senovilla,Elisa E. Baracco,Norma Bloy,Francesca Castoldi,Jean Pierre Abastado,Patrizia Agostinis,Ron N. Apte,Fernando Aranda,Maha Ayyoub,Philipp Beckhove,Jean-Yves Blay,Laura Bracci,Anne Caignard,Chiara Castelli,Federica Cavallo,Estaban Celis,Vincenzo Cerundolo,Aled Clayton,Mario P. Colombo,Lisa M. Coussens,Madhav V. Dhodapkar,Alexander M.M. Eggermont,Douglas T. Fearon,Wolf H. Fridman,Jitka Fucikova,Dmitry I. Gabrilovich,Jérôme Galon,Abhishek D. Garg,François Ghiringhelli,François Ghiringhelli,Giuseppe Giaccone,Giuseppe Giaccone,Eli Gilboa,Sacha Gnjatic,Axel Hoos,Anne Hosmalin,Anne Hosmalin,Anne Hosmalin,Dirk Jäger,Pawel Kalinski,Klas Kärre,Oliver Kepp,Rolf Kiessling,John M. Kirkwood,Eva Klein,Alexander Knuth,Claire E. Lewis,Roland S. Liblau,Roland S. Liblau,Roland S. Liblau,Michael T. Lotze,Enrico Lugli,Jean-Pierre Mach,Fabrizio Mattei,Domenico Mavilio,Ignacio Melero,Cornelis J. M. Melief,E. A. Mittendorf,Lorenzo Moretta,Adekunke Odunsi,Hideho Okada,Anna Karolina Palucka,Marcus E. Peter,Kenneth J. Pienta,Angel Porgador,George C. Prendergast,George C. Prendergast,Gabriel A. Rabinovich,Nicholas P. Restifo,Naiyer A. Rizvi,Catherine Sautès-Fridman,Hans Schreiber,Barbara Seliger,Hiroshi Shiku,Bruno Silva-Santos,Mark J. Smyth,Mark J. Smyth,Daniel E. Speiser,Daniel E. Speiser,Radek Spisek,Pramod K. Srivastava,James E. Talmadge,Eric Tartour,Sjoerd H. van der Burg,Benoît Van den Eynde,Benoît Van den Eynde,Richard G. Vile,Hermann Wagner,Jeffrey S. Weber,Theresa L. Whiteside,Jedd D. Wolchok,Jedd D. Wolchok,Laurence Zitvogel,Weiping Zou,Guido Kroemer +98 more
TL;DR: A critical, integrated classification of anticancer immunotherapies is proposed and the clinical relevance of these approaches is discussed.
Journal ArticleDOI
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Laurie Menger,Erika Vacchelli,Erika Vacchelli,Erika Vacchelli,Sandy Adjemian,Sandy Adjemian,Sandy Adjemian,Isabelle Martins,Isabelle Martins,Isabelle Martins,Yuting Ma,Yuting Ma,Yuting Ma,Shensi Shen,Shensi Shen,Shensi Shen,Takahiro Yamazaki,Takahiro Yamazaki,Takahiro Yamazaki,Abdul Qader Sukkurwala,Abdul Qader Sukkurwala,Abdul Qader Sukkurwala,Mickaël Michaud,Mickaël Michaud,Mickaël Michaud,Grégoire Mignot,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Eric Sulpice,Clara Locher,Clara Locher,Clara Locher,Xavier Gidrol,François Ghiringhelli,Nazanine Modjtahedi,Nazanine Modjtahedi,Nazanine Modjtahedi,Lorenzo Galluzzi,Lorenzo Galluzzi,Fabrice Andre,Fabrice Andre,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Oliver Kepp,Oliver Kepp,Oliver Kepp,Guido Kroemer +48 more
TL;DR: Rec retrospective clinical analyses revealed that the administration of the CG digoxin during chemotherapy had a positive impact on overall survival in cohorts of breast, colorectal, head and neck, and hepatocellular carcinoma patients, especially when they were treated with agents other than anthracyclines and oxaliplatin.
Journal ArticleDOI
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
TL;DR: The literature on the immunogenic effects of platinum is reviewed, the clinical advances using platinum as a cytotoxic compound with immune adjuvant properties are summarized, the limitations to these studies are discussed, and the gaps in the understanding of the immunologic effects of these drugs are discussed.
References
More filters
Journal ArticleDOI
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
Richard J. Sylvester,Maurizio A. Brausi,Wim J. Kirkels,Wolfgang Hoeltl,Fernando Calais da Silva,Philip Powell,Stephen Prescott,Ziya Kirkali,Cees van de Beek,Thierry Gorlia,Theo M. de Reijke +10 more
TL;DR: In patients with intermediate- and high-risk stage Ta and T1 urothelial bladder cancer, intravesical BCG with or without INH is superior to intravesicals epirubicin not only for time to first recurrence but also for timeto distant metastases, overall survival, and disease-specific survival.
Journal ArticleDOI
In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity
Martijn H. den Brok,Roger P.M. Sutmuller,Robbert van der Voort,Erik Bennink,Carl G. Figdor,Theo J.M. Ruers,Gosse J. Adema +6 more
TL;DR: It is demonstrated that following RFA, a weak but detectable immune response develops, directed against OVA, but also against a broader range of B16 antigens, and this strongly enhanced antitumor immunity, resulting in long-lasting tumor protection.
Journal Article
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial
A. Ritchie,Gareth Griffiths,M K B Parmar,Sophie D. Fosså,Peter Selby,MA Cornbleet,G Sibley,Graham M. Mead,Stan B. Kaye,Owen,R T D Oliver,Pete Smith,P Whelan,P. A. Cook,Peter Fayers,P. A. Cook,J Webb,John Whitehead,A Lamont +18 more
TL;DR: The benefit of treatment with interferon-oc should be weighed against the drug's toxic effects and combined regimens of biological therapy and chemotherapy should now be compared with interferential monotherapy in randomised controlled trials.
Journal ArticleDOI
Designing vaccines based on biology of human dendritic cell subsets.
TL;DR: Increased understanding of the mechanisms of antigen presentation, particularly with the description of DC subsets with distinct functions, as well as their plasticity in responding to extrinsic signals, will permit us to design vaccines that will reprogram the immune system to intervene therapeutically in cancer, allergy, and autoimmunity.
Journal ArticleDOI
Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod
Manon van Seters,Marc van Beurden,Fiebo J.W. ten Kate,Ilse Beckmann,Patricia C. Ewing,Marinus J.C. Eijkemans,Marjolein J. Kagie,Chris J L M Meijer,Neil K. Aaronson,Alex KleinJan,Claudia Heijmans-Antonissen,Freek J. Zijlstra,Matthé P.M. Burger,Theo J.M. Helmerhorst +13 more
TL;DR: Imiquimod 5% cream is effective in the treatment of vulvar intraepithelial neoplasia and reduces pruritus and pain at 20 weeks and remained free from disease at 12 months.
Related Papers (5)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more